Literature DB >> 24114434

Improvement of selective screening strategy for gestational diabetes through a more accurate definition of high-risk groups.

Basilio Pintaudi1, Giacoma Di Vieste, Francesco Corrado, Giuseppe Lucisano, Fabio Pellegrini, Loretta Giunta, Antonio Nicolucci, Rosario D'Anna, Antonino Di Benedetto.   

Abstract

OBJECTIVE: This study aimed to assess the predictive value of risk factors (RFs) for gestational diabetes mellitus (GDM) established by selective screening (SS) and to identify subgroups of women at a higher risk of developing GDM.
DESIGN: A retrospective, single-center study design was employed.
METHODS: Data of 1015 women screened for GDM at 24-28 weeks of gestation and diagnosed according to the International Association of Diabetes and Pregnancy Study Groups criteria were evaluated. Information on RFs established by SS was also collected and their association with GDM was determined. To identify distinct and homogeneous subgroups of patients at a higher risk, the RECursive Partitioning and AMalgamation (RECPAM) method was used.
RESULTS: Overall, 113 (11.1%) women were diagnosed as having GDM. The application of the SS criteria would result in the execution of an oral glucose tolerance test (OGTT) in 58.3% of women and 26 (23.0%) cases of GDM would not be detected due to the absence of any RF. The RECPAM analysis identified high-risk subgroups characterized by fasting plasma glucose values >5.1 mmol/l (odds ratio (OR)=26.5; 95% CI 14.3-49.0) and pre-pregnancy BMI (OR=7.0; 95% CI 3.9-12.8 for overweight women). In a final logistic model including RECPAM classes, previous macrosomia (OR=3.6; 95% CI 1.1-11.6), and family history of diabetes (OR=1.8; 95% CI 1.1-2.8), but not maternal age, were also found to be associated with an increased risk of developing GDM. A screening approach based on the RECPAM model would reduce by over 50% (23.0 vs 10.6%) the number of undiagnosed GDM cases when compared with the current SS approach, at the expense of 50 additional OGTTs required.
CONCLUSIONS: A screening approach based on our RECPAM model results in a significant reduction in the number of undetected GDM cases compared with the current SS procedure.

Entities:  

Mesh:

Year:  2013        PMID: 24114434     DOI: 10.1530/EJE-13-0759

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  11 in total

1.  Fasting plasma glucose level to guide the need for an OGTT to screen for gestational diabetes mellitus.

Authors:  Kaat Beunen; Astrid Neys; Paul Van Crombrugge; Carolien Moyson; Johan Verhaeghe; Sofie Vandeginste; Hilde Verlaenen; Chris Vercammen; Toon Maes; Els Dufraimont; Nele Roggen; Christophe De Block; Yves Jacquemyn; Farah Mekahli; Katrien De Clippel; Annick Van Den Bruel; Anne Loccufier; Annouschka Laenen; Roland Devlieger; Chantal Mathieu; Katrien Benhalima
Journal:  Acta Diabetol       Date:  2021-11-01       Impact factor: 4.280

Review 2.  High Fasting Plasma Glucose during Early Pregnancy: A Review about Early Gestational Diabetes Mellitus.

Authors:  E Cosson; L Carbillon; P Valensi
Journal:  J Diabetes Res       Date:  2017-10-18       Impact factor: 4.011

Review 3.  Risk factor screening to identify women requiring oral glucose tolerance testing to diagnose gestational diabetes: A systematic review and meta-analysis and analysis of two pregnancy cohorts.

Authors:  Diane Farrar; Mark Simmonds; Maria Bryant; Debbie A Lawlor; Fidelma Dunne; Derek Tuffnell; Trevor A Sheldon
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

Review 4.  Prediction models for the risk of gestational diabetes: a systematic review.

Authors:  Marije Lamain-de Ruiter; Anneke Kwee; Christiana A Naaktgeboren; Arie Franx; Karel G M Moons; Maria P H Koster
Journal:  Diagn Progn Res       Date:  2017-02-08

5.  Protocol for a randomized controlled trial of pre-pregnancy lifestyle intervention to reduce recurrence of gestational diabetes: Gestational Diabetes Prevention/Prevención de la Diabetes Gestacional.

Authors:  Suzanne Phelan; Elissa Jelalian; Donald Coustan; Aaron B Caughey; Kristin Castorino; Todd Hagobian; Karen Muñoz-Christian; Andrew Schaffner; Laurence Shields; Casey Heaney; Angelica McHugh; Rena R Wing
Journal:  Trials       Date:  2021-04-07       Impact factor: 2.279

6.  Screening of postpartum diabetes in women with gestational diabetes: high-risk subgroups and areas for improvements-the STRONG observational study.

Authors:  Angela Napoli; Laura Sciacca; Basilio Pintaudi; Andrea Tumminia; Maria Grazia Dalfrà; Camilla Festa; Gloria Formoso; Raffaella Fresa; Giusi Graziano; Cristina Lencioni; Antonio Nicolucci; Maria Chiara Rossi; Elena Succurro; Maria Angela Sculli; Marina Scavini; Ester Vitacolonna; Matteo Bonomo; Elisabetta Torlone
Journal:  Acta Diabetol       Date:  2021-04-12       Impact factor: 4.280

7.  Machine Learning Prediction Models for Gestational Diabetes Mellitus: Meta-analysis.

Authors:  Zheqing Zhang; Luqian Yang; Wentao Han; Yaoyu Wu; Linhui Zhang; Chun Gao; Kui Jiang; Yun Liu; Huiqun Wu
Journal:  J Med Internet Res       Date:  2022-03-16       Impact factor: 7.076

8.  Performance of early risk assessment tools to predict the later development of gestational diabetes.

Authors:  Grammata Kotzaeridi; Julia Blätter; Daniel Eppel; Ingo Rosicky; Martina Mittlböck; Gülen Yerlikaya-Schatten; Christian Schatten; Peter Husslein; Wolfgang Eppel; Evelyn A Huhn; Andrea Tura; Christian S Göbl
Journal:  Eur J Clin Invest       Date:  2021-06-18       Impact factor: 5.722

Review 9.  The Oral Glucose Tolerance Test-Is It Time for a Change?-A Literature Review with an Emphasis on Pregnancy.

Authors:  Delia Bogdanet; Paula O'Shea; Claire Lyons; Amir Shafat; Fidelma Dunne
Journal:  J Clin Med       Date:  2020-10-27       Impact factor: 4.241

10.  Gestational Diabetes Mellitus in Europe: A Systematic Review and Meta-Analysis of Prevalence Studies.

Authors:  Marília Silva Paulo; Noor Motea Abdo; Rita Bettencourt-Silva; Rami H Al-Rifai
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-09       Impact factor: 6.055

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.